Monthly
US$200
Billed every month
Adapalene Gel(阿达帕林凝胶)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationAccepted: 3 applicationsNo longer listed under review: 1 applicationSupplement delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders0View records ↓
Under-review filings31View records ↓
This year’s generic filers9View records ↓
NHSA approval numbers19View records ↓
API companies with A status10View records ↓
Chemical-drug catalogue
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 19 distinct approval numbers and 19 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 津药和平(天津)制药有限公司 | 国药准字H20083655 | 0.1% | Category B (乙) | XD10ADA013U001010100952 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20113373 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010101438 | NHSA |
| 苏州天马医药集团天吉生物制药有限公司 | 国药准字H20263906 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010101669 | NHSA |
| 湖北科田药业有限公司 | 国药准字H20264733 | 0.1% (30g:30mg) | Category B (乙) | XD10ADA013U001010101827 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010101955 | NHSA |
| 四川明欣药业有限责任公司 | 国药准字H20065544 | 15g:15mg | Category B (乙) | XD10ADA013U001010102029 | NHSA |
| 华东医药(西安)博华制药有限公司 | 国药准字H20264683 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010102469 | NHSA |
| 黑龙江福和制药集团股份有限公司 | 国药准字H20056871 | 0.1% | Category B (乙) | XD10ADA013U001010103731 | NHSA |
| 万全万特制药江苏有限公司 | 国药准字H20066621 | 0.1% | Category B (乙) | XD10ADA013U001010105826 | NHSA |
| Laboratoires GALDERMA | H20160022 | 0.1% | Category B (乙) | XD10ADA013U001010178442 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20183078 | 0.1%(10g:10mg) | Category B (乙) | XD10ADA013U001010180088 | NHSA |
| 福元药业有限公司 | 国药准字H20183400 | 0.1%(15g:15mg) | Category B (乙) | XD10ADA013U001010180651 | NHSA |
| 浙江普利药业有限公司 | 国药准字H20264897 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010182922 | NHSA |
| 海南诚锐生物科技有限公司 | 国药准字H20263559 | 0.1%(30克:30毫克) | Category B (乙) | XD10ADA013U001010183945 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264035 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010184221 | NHSA |
| 苏州高迈药业有限公司 | 国药准字H20249038 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010184410 | NHSA |
| 杭州领业医药科技有限公司 | 国药准字H20255217 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010184874 | NHSA |
| 苏州天马医药集团天吉生物制药有限公司 | 国药准字H20263906 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010201669 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001010201955 | NHSA |
| 津药和平(天津)制药有限公司 | 国药准字H20083655 | 0.1% | Category B (乙) | XD10ADA013U001020100952 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20113373 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001020101438 | NHSA |
| 湖北科田药业有限公司 | 国药准字H20264733 | 0.1% (30g:30mg) | Category B (乙) | XD10ADA013U001020101827 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001020101955 | NHSA |
| 四川明欣药业有限责任公司 | 国药准字H20065544 | 15g:15mg | Category B (乙) | XD10ADA013U001020102029 | NHSA |
| 黑龙江福和制药集团股份有限公司 | 国药准字H20056871 | 0.1% | Category B (乙) | XD10ADA013U001020103731 | NHSA |
| 万全万特制药江苏有限公司 | 国药准字H20066621 | 0.1% | Category B (乙) | XD10ADA013U001020105826 | NHSA |
| Galderma International | 国药准字HJ20160022 | 0.1% | Category B (乙) | XD10ADA013U001020178442 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20183078 | 0.1%(10g:10mg) | Category B (乙) | XD10ADA013U001020180088 | NHSA |
| 福元药业有限公司 | 国药准字H20183400 | 0.1%(15g:15mg) | Category B (乙) | XD10ADA013U001020180651 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20113373 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001030101438 | NHSA |
| 江苏小林制药有限公司 | 国药准字H20064230 | 0.1%(30克:30毫克,以C28H28O3计) | Category B (乙) | XD10ADA013U001030101526 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001030101955 | NHSA |
| 四川明欣药业有限责任公司 | 国药准字H20065544 | 15g:15mg | Category B (乙) | XD10ADA013U001030102029 | NHSA |
| 万全万特制药江苏有限公司 | 国药准字H20066621 | 0.1% | Category B (乙) | XD10ADA013U001030105826 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20183078 | 0.1%(10g:10mg) | Category B (乙) | XD10ADA013U001030180088 | NHSA |
| 福元药业有限公司 | 国药准字H20183400 | 0.1%(15g:15mg) | Category B (乙) | XD10ADA013U001030180651 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20113373 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001040101438 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001040101955 | NHSA |
| 万全万特制药江苏有限公司 | 国药准字H20066621 | 0.1% | Category B (乙) | XD10ADA013U001040105826 | NHSA |
| 福元药业有限公司 | 国药准字H20183400 | 0.1%(15g:15mg) | Category B (乙) | XD10ADA013U001040180651 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20113373 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001050101438 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001050101955 | NHSA |
| 万全万特制药江苏有限公司 | 国药准字H20066621 | 0.1% | Category B (乙) | XD10ADA013U001050105826 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20113373 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001060101438 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001060101955 | NHSA |
| 万全万特制药江苏有限公司 | 国药准字H20066621 | 0.1% | Category B (乙) | XD10ADA013U001060105826 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001060201955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001060301955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001060401955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001060501955 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20113373 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001070101438 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001070101955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001080101955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001090101955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001090201955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001100101955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001110101955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001120101955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001130101955 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20173406 | 0.1%(30g:30mg) | Category B (乙) | XD10ADA013U001140101955 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 31 filings and 30 distinct first applicants.
Generic 27 · Supplement 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏知原药业股份有限公司 | CYHS2401107 | Generic | 2024/04/13 | Not stated by source | CDE |
| 江苏迪赛诺制药有限公司 | CYHS2600245 | Generic | 2026/01/22 | Not stated by source | CDE |
| 苏州高迈药业有限公司;药源生物科技（启东）有限公司 | CYHB2601521 | Supplement | 2026/08/11 | Not stated by source | CDE |
| 乐福思健康产业股份公司;药源生物科技（启东）有限公司 | CYHS2601221 | Generic | 2026/06/01 | Not stated by source | CDE |
| 江苏盈科生物制药有限公司 | CYHS2501533 | Generic | 2025/04/23 | Not stated by source | CDE |
| 苏州第四制药厂有限公司 | CYHS2502063 | Generic | 2025/06/11 | Not stated by source | CDE |
| 杭州领业医药科技有限公司 | CYHB2601900 | Supplement | 2026/10/15 | Not stated by source | CDE |
| Galderma International;Laboratoires Galderma | JYHB2600483 | Supplement | 2026/08/20 | Not stated by source | CDE |
| 黑龙江天辰药业有限公司 | CYHS2601910 | Generic | 2026/08/06 | Not stated by source | CDE |
| 江西施美药业股份有限公司 | CYHS2601760 | Generic | 2026/07/22 | Not stated by source | CDE |
| 山东明仁福瑞达制药股份有限公司 | CYHS2601755 | Generic | 2026/07/22 | Not stated by source | CDE |
| 湖南状元制药有限公司;马应龙药业集团股份有限公司 | CYHS2601740 | Generic | 2026/07/21 | Not stated by source | CDE |
| 津药药业股份有限公司;津药和平（天津）制药有限公司 | CYHS2601093 | Generic | 2026/05/13 | Not stated by source | CDE |
| 津药药业股份有限公司;津药和平（天津）制药有限公司 | CYHS2601092 | Generic | 2026/05/13 | Not stated by source | CDE |
| 曼秀雷敦（中国）药业有限公司;华东医药(西安)博华制药有限公司 | CYHB2600614 | Supplement | 2026/03/28 | Not stated by source | CDE |
| 山东辰欣佛都药业股份有限公司 | CYHS2600452 | Generic | 2026/02/11 | Not stated by source | CDE |
| 浙江华海药业股份有限公司 | CYHS2600150 | Generic | 2026/01/12 | Not stated by source | CDE |
| 湖北长江瑞益医药科技有限公司;远大医药（仙桃）制药有限公司 | CYHS2504340 | Generic | 2025/12/22 | Not stated by source | CDE |
| 国药控股鑫烨（湖北）医药有限公司;湖北广济药业股份有限公司 | CYHS2503608 | Generic | 2025/10/10 | Not stated by source | CDE |
| 北京京丰制药（河北）有限公司 | CYHS2503135 | Generic | 2025/08/27 | Not stated by source | CDE |
| 东阳祥昇医药科技有限公司;浙江赛默制药有限公司 | CYHS2503007 | Generic | 2025/08/16 | Not stated by source | CDE |
| 河北三禾实创生物科技有限公司;广东华润顺峰药业有限公司 | CYHS2502934 | Generic | 2025/08/12 | Not stated by source | CDE |
| 广州乐宓医药科技有限公司;南昌立健药业有限公司 | CYHS2502851 | Generic | 2025/08/06 | Not stated by source | CDE |
| 乐泰药业（兰西）有限公司 | CYHS2501879 | Generic | 2025/05/27 | Not stated by source | CDE |
| 浙江寰领医药科技有限公司 | CYHS2501614 | Generic | 2025/04/30 | Not stated by source | CDE |
| 唐山红星药业有限责任公司 | CYHS2501604 | Generic | 2025/04/29 | Not stated by source | CDE |
| 成都市海通药业有限公司 | CYHS2501372 | Generic | 2025/04/10 | Not stated by source | CDE |
| 杭州和泽坤元药业有限公司;华东医药（西安）博华制药有限公司 | CYHS2500469 | Generic | 2025/01/24 | Not stated by source | CDE |
| 浙江康恩贝制药股份有限公司 | CYHS2403888 | Generic | 2024/11/13 | Not stated by source | CDE |
| 海南全星制药有限公司 | CYHS2402972 | Generic | 2024/09/10 | Not stated by source | CDE |
| 山东良福制药有限公司 | CYHS2401880 | Generic | 2024/06/25 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 10 filings and 9 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏迪赛诺制药有限公司 | CYHS2600245 | Generic | 2026/01/22 | Not stated by source | CDE |
| 乐福思健康产业股份公司;药源生物科技（启东）有限公司 | CYHS2601221 | Generic | 2026/06/01 | Not stated by source | CDE |
| 黑龙江天辰药业有限公司 | CYHS2601910 | Generic | 2026/08/06 | Not stated by source | CDE |
| 江西施美药业股份有限公司 | CYHS2601760 | Generic | 2026/07/22 | Not stated by source | CDE |
| 山东明仁福瑞达制药股份有限公司 | CYHS2601755 | Generic | 2026/07/22 | Not stated by source | CDE |
| 湖南状元制药有限公司;马应龙药业集团股份有限公司 | CYHS2601740 | Generic | 2026/07/21 | Not stated by source | CDE |
| 津药药业股份有限公司;津药和平（天津）制药有限公司 | CYHS2601093 | Generic | 2026/05/13 | Not stated by source | CDE |
| 津药药业股份有限公司;津药和平（天津）制药有限公司 | CYHS2601092 | Generic | 2026/05/13 | Not stated by source | CDE |
| 山东辰欣佛都药业股份有限公司 | CYHS2600452 | Generic | 2026/02/11 | Not stated by source | CDE |
| 浙江华海药业股份有限公司 | CYHS2600150 | Generic | 2026/01/12 | Not stated by source | CDE |
API registrations
Non-component matches: 10 companies with A status and 3 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 阿达帕林 | Maithri Drugs Private Limited | Y20250000080 | I | Exact ingredient | 2025/02/05 | CDE |
| 阿达帕林 | 扬州市三药制药有限公司 | Y20250000095 | A | Exact ingredient | 2026/08/28 | CDE |
| 阿达帕林 | 乳源东阳光药业有限公司 | Y20230000833 | A | Exact ingredient | 2026/06/02 | CDE |
| 阿达帕林 | 宜昌诺安制药有限公司 | Y20220000364 | A | Exact ingredient | 2026/03/11 | CDE |
| 阿达帕林 | Aarti Pharmalabs Limited | Y20200001052 | A | Exact ingredient | 2026/06/27 | CDE |
| 阿达帕林 | Glenmark Life Sciences Limited | Y20190000839 | I | Exact ingredient | 2024/02/20 | CDE |
| 阿达帕林 | 江苏联环药业股份有限公司 | Y20190009578 | A | Exact ingredient | 2023/03/24 | CDE |
| 阿达帕林 | 黑龙江福和制药集团股份有限公司 | Y20190008778 | A | Exact ingredient | 2024/03/15 | CDE |
| 阿达帕林 | 津药药业股份有限公司 | Y20190008276 | A | Exact ingredient | 2023/03/24 | CDE |
| 阿达帕林 | 万特制药（海南）有限公司 | Y20190008174 | A | Exact ingredient | 2025/10/10 | CDE |
| 阿达帕林 | 江苏恒润制药有限公司 | Y20170001870 | I | Exact ingredient | 2018/09/10 | CDE |
| 阿达帕林 | 重庆胜凯制药有限公司 | Y20170002274 | A | Exact ingredient | 2025/06/21 | CDE |
| 阿达帕林 | 四川百利药业有限责任公司 | Y20170001351 | A | Exact ingredient | 2023/03/24 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/24No longer listed under review
江苏小林制药有限公司
CYHB2601800
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2026/09/22
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/22); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 27
NMPA · Table row 27 ↗ View source ↗ -
2026/10/22Supplement delivery
江苏小林制药有限公司
CYHB2601800
Fact date: 2026/10/22 · Publication date: 2026/10/23 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 27 ↗ -
2026/10/20Marketing application approved
广东仁想药业有限公司
CYHS2501238 · 国药准字H20266314
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 47 ↗ -
2026/10/15Accepted
-
2026/09/22Accepted
-
2026/08/20Accepted
Galderma International;Laboratoires Galderma
JYHB2600483
Fact date: 2026/08/20 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Adapalene Gel
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy